
PACIFIC BIOSCIENCES OF CALIF
PACBNASDAQTrading Snapshot
- Day Range
- $1.07 β $1.09
- 52-Week Range
- $1.09 β $2.73
- Volume
- $2.70B
- Avg Volume
- $2.99B
- Shares Outstanding
- 310.6M
- Next Earnings
- Oct 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $160M
- Last Q Revenue
- $39M
- P/E Ratio
- -2.7
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-0.42
- Dividend Yield
- 0.00%
Why Investors Own PACB
- βHigh-growth profile β revenue up +51.6% YoY with expanding US Equity exposure.
- βHealthy economics β 29% gross margin and 28% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PACIFIC BIOSCIENCES OF CALIF
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

Pacific Biosciences of California, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-08. The following slide deck was published by Pacific Biosciences of California, Inc.

Pacific Biosciences: It's Only Getting Worse
Pacific Biosciences reported Q2 revenues of $39.01M, missing estimates and guiding 2026 revenues down, below consensus. Read why PACB stock is a Sell.

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsChristian Henry - President, CEO &...
Pacific Biosciences (NASDAQ:PACB) Shares Drop After Q2 Revenue Miss
PacBio Q2 results miss estimates; revenue $39M vs $40.9M expected, EPS loss wider. Shares drop ~4% after hours. New CEO named.
Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuring plan to continue to better align the Companyβs organizational structure and resources with its strategic
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.